In 101 patients receiving gemcitabine at any time during study treatment ( either within the 1st - or 2nd-line setting ) hENT1 ( low ) cases had a median overall survival of 7.5 months and hENT1 ( high ) patients an overall survival of 4.4 months ( HR 1.30 , 95 % CI 0.84-2 .03 , p = 0.24 ) , respectively .